Real-world effectiveness of ixekizumab in mild, moderate, and severe psoriasis: The patient perspective

Alice B. Gottlieb1, Russel Burge2, William N. Malatestinic3, Baojin Zhu2, Yunnyang Zhao2, Julie McCormack4, Miriam Kimel2, Meghan Feely2, Joseph F. Merola4
1Icahn School of Medicine at Mount Sinai, New York, USA; 2Eli Lilly and Company, Indianapolis, USA; 3Evidera, Bethesda, USA; and 4Harvard Medical School, Brigham and Women’s Hospital, Boston, USA

DISCUSSION

- Improvement in all outcome measures were observed by Week 24 across all severities of psoriasis
  - Similar improvements were observed across the subgroups: biologic use, PsA status, and Ps4 nail involvement at baseline
  - With a real-world study population, factors influencing outcomes may include, but are not limited to, self-reported psoriasis, compliance with medications, and experience with biologics

CONCLUSIONS

- In a real-world setting, PRO improvements have been observed across all severities of psoriasis, with the greatest improvements observed in patients with severe psoriasis

METHODS

US Ixekizumab CSP Design

Key Eligibility Criteria

- Patients with psoriasis enrolled in the US Ixekizumab CSP
- ≥18 years of age
- Commercial insurance
- Initiated ixekizumab within 7 days of screening
- Device with access to the internet

Assessments

- Web-based questionnaires administered at baseline, Weeks 2, 4, 8, 12, and 24
- Data collection from the US Ixekizumab Customer Support Program (CSP) aims to create a large, patient-reported US database to fill this information gap

Patient Demographics and Baseline Characteristics

- Age
- Sex
- BMI
- Psoriatic arthritis
- Psoriasis severity
- Psoriasis duration
- Psoriasis location
- Psoriasis severity

Statistical Analyses

- PROs were assessed through Week 24
- Changes from baseline were evaluated with a paired t-test
- Data are reported for the overall study population
- No data imputation was performed

REFERENCES

3. Winter Clinical Dermatology Conference (WCDC); Kohala Coast, USA; 13-18 January 2023
4. Icahn School of Medicine at Mount Sinai, New York, USA; 2Eli Lilly and Company, Indianapolis, USA; 3Evidera, Bethesda, USA; and 4Harvard Medical School, Brigham and Women’s Hospital, Boston, USA

Winter Clinical Dermatology Conference (WCDC); Kohala Coast, USA; 13-18 January 2023

Studied was sponsored by Eli Lilly and Company

Scan or click the QR code or use this URL: (https://lillyscience.lilly.com/congress/wcdc2023) for a list of all study content presented at the congress.

Other companies and product names are trademarks of their respective owners.